Name: Fluvastatin Sodium
Brand: Selleck Chemicals
SKU: S1909
Rating: 5 (26 reviews)

Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other HMG-CoA Reductase Inhibitors	Mevastatin SR-12813 Clinofibrate Dihydrolanosterol 7-ketocholesterol Cerivastatin sodium

Chemical Information, Storage & Stability

Molecular Weight	433.45	Formula	C₂₄H₂₅FNNaO₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	93957-55-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	XU-62-320 Sodium			Smiles	CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+]

Solubility

In vitro
Batch:

DMSO : 87 mg/mL (200.71 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 18 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	30%propylene glycol 1 5%Tween80 2 65%D5W Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	30.000mg/ml (69.21mM)	Taking the 1 mL working solution as an example, add 300 μL of 100 mg/ml clarified propylene glycol stock solution to 50 μL of Tween 80, mix evenly to clarify it; then continue to add 650 μL of D5W to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Features	The order of magnitude of inhibition of each drug on the peroxidation was butylated hydroxytoluene > fluvastatin ≥ probucol ≥ pravastatin.
Targets/IC₅₀/Ki	HMG-CoA reductase (Cell-free assay) 8 nM
In vitro	Fluvastatin markedly inhibits the formation of thiobarbituric acid reactive substances in iron (II)-supported peroxidation of liposomes with IC50 of 12 μM. Fluvastatin ranging from 1 μM to 100 μM inhibits peroxyl radical-mediated peroxidation of liposomes induced by water-soluble and lipid-soluble radical generators, 2,2'-azobis (2-amidinopropane) dihydro-chloride and 2,2'-azobis (2,4-dimethylvaleronitrile), respectively. Fluvastatin (4 mM) and its metabolites shows superoxide anion scavenging activity in the hypoxanthine-xanthine oxidase system and a strong scavenging effect on the hydroxyl radical produced from Fenton's reaction. Fluvastatin (8 μM) and its metabolites shows protective effects on DNA damage as potent as the reference antioxidants, ascorbic acid, trolox, and probucol in CHL/IU cells. Fluvastatin (100 nM) shows a dose-dependent decrease in Ang II-activated superoxide anion formation in human aortic smooth muscle cells (hASMC).
In vivo	Fluvastatin (10 mg/kg/day) results in a decrease in serum lipids in rabbits feed a 1.5% cholesterol containing diet. Fluvastatin (10 mg/kg/day) significantly lowers the tissue ACE in the aortae in rabbits feed a 1.5% cholesterol containing diet. Fluvastatin (10 mg/kg/day) significantly reverses the suppression of ACh-induced relaxation in rabbits feed a 1.5% cholesterol containing diet.
References	[1] https://pubmed.ncbi.nlm.nih.gov/10965989/ [2] https://pubmed.ncbi.nlm.nih.gov/11273020/ [3] https://pubmed.ncbi.nlm.nih.gov/11811530/ [4] https://pubmed.ncbi.nlm.nih.gov/12374897/ [5] https://pubmed.ncbi.nlm.nih.gov/8937733/

Applications

Methods	Biomarkers	PMID
Growth inhibition assay	Cell viability	26199863
Western blot	p53 / p21 / Cyclin D1 / ATF3 / H3P / PARP / Cleaved PARP / γ-H2AX YAP1 / TAZ / RHAMM	30939155
Immunofluorescence	YAP1	29212185

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02115074	Completed	Glioma	Centre Oscar Lambret\|Anticancer Fund Belgium	June 2014	Phase 1
NCT01524601	Completed	Disorder Related to Renal Transplantation\|Hypercholesterolemia	University of Oslo School of Pharmacy\|Oslo University Hospital	February 2012	Phase 4
NCT00814606	Withdrawn	Hepatitis C\|Hepatitis C Virus	University of Chicago	February 2010	Phase 2
NCT00752843	Completed	Healthy Subjects	Corcept Therapeutics	September 2008	Phase 1
NCT00674297	Completed	Antiphospholipid Syndrome	Hospital for Special Surgery New York\|University of Texas	May 2008	Phase 2
NCT00404287	Terminated	Aortic Valve Stenosis	AORTICA Group	October 1 2006	Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Fluvastatin Sodium HMG-CoA Reductase inhibitor

Chemical Structure

Molecular Weight: 433.45